Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alzheimer's disease
4
×
biotech
4
×
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
cancer
4
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
4
×
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
4
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biogen
deals
eli lilly
gilead sciences
abbvie
aducanumab
aduro biotech
cancer immunotherapy
diagnostics
What
bio
roundup
drug
companies
new
price
acquisitions
activity
alzheimer’s
approval
approvals
biggest
biogen
biogen’s
biopharmaceutical
build
buy
ceo
clamped
company’s
convo
covid
daniel
debut
delays
developing
different
dyne’s
earlier
economic
fail
failures
fast
fda
gene
gilead
including
increases
ipo
isn’t
Language
unset
Current search:
biotech
×
novartis
×
cancer
×
" indiana top stories "
×
" alzheimer's disease "
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More